- Home
- SENEA vs VALN Comparison
SENEA vs VALN Comparison
Compare SENEA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | VALN |
|---|---|---|
| Founded | 1949 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 820.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SENEA | VALN |
|---|---|---|
| Price | $111.72 | $8.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 82.1K | 20.4K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $211,089,992.00 |
| Revenue This Year | N/A | $5.08 |
| Revenue Next Year | N/A | $12.53 |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | 8.33 | ★ 13.48 |
| 52 Week Low | $70.58 | $3.62 |
| 52 Week High | $129.03 | $12.25 |
Technical Indicators
Market Signals| Indicator | SENEA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 41.84 |
| Support Level | $109.05 | $8.62 |
| Resistance Level | $113.83 | $9.10 |
| Average True Range (ATR) | 4.27 | 0.29 |
| MACD | -1.18 | 0.01 |
| Stochastic Oscillator | 14.01 | 0.00 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.